Involvement of heparanase in the pathogenesis of acute kidney injury: Nephroprotective effect of PG545 by Abassi, Zaid et al.
Original Citation:
Involvement of heparanase in the pathogenesis of acute kidney injury: Nephroprotective effect of PG545
Impact Journals LLC
Publisher:
Published version:
DOI:
Terms of use:
Open Access
(Article begins on next page)
This article is made available under terms and conditions applicable to Open Access Guidelines, as described at
http://www.unipd.it/download/file/fid/55401 (Italian only)
Availability:
This version is available at: 11577/3235697 since: 2017-06-21T12:21:47Z
10.18632/oncotarget.16573
Università degli Studi di Padova
Padua Research Archive - Institutional Repository
Oncotarget34191www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 21), pp: 34191-34204
Involvement of heparanase in the pathogenesis of acute kidney 
injury: nephroprotective effect of PG545
Zaid Abassi1,2, Shadi Hamoud3, Ahmad Hassan4, Iyad Khamaysi5, Omri Nativ1, 
Samuel N. Heyman6, Rabia Shekh Muhammad3, Neta Ilan7, Preeti Singh7, Edward 
Hammond8, Gianluigi Zaza9, Antonio Lupo9, Maurizio Onisto10, Gloria Bellin9, 
Valentina Masola9, Israel Vlodavsky7 and Giovani Gambaro11
1 Department of Physiology, The Rappaport Faculty of Medicine, Technion, Haifa, Israel
2 Department of Laboratory Medicine, Rambam Health Care Campus, Haifa, Israel
3 Department of Internal Medicine E, Rambam Health Care Campus, Haifa, Israel
4 Department of Internal Medicine A, Rambam Health Care Campus, Haifa, Israel
5 Department of Gastroenterology, Rambam Health Care Campus, Haifa, Israel
6 Department of Internal Medicine, Hebrew University-Hadassah Medical Center, Jerusalem, Israel
7 Department of Cancer and Vascular Biology Research Center, The Rappaport Faculty of Medicine, Technion, Haifa, Israel
8 Zucero Therapeutics, Brisbane, Queensland, Australia
9 Department of Medicine, Renal Unit, Verona, Italy
10 Department of Biomedical Sciences, University of Padova, Catholic University of the Sacred Heart, Roma, Italy
11 Department of Medicine, Columbus-Gemelli Hospital, Catholic University of the Sacred Heart, Roma, Italy 
Correspondence to: Zaid Abassi, email: abassi@tx.technion.ac.il
Correspondence to: Israel Vlodavsky, email: vlodavsk@cc.huji.ac.il
Keywords: acute kidney injury, heparanase, ischemia, inflammation, PG545
Received: February 09, 2017 Accepted: March 16, 2017 Published: March 25, 2017
Copyright: Abassi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC-BY), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ABSTRACT
Despite the high prevalence of acute kidney injury (AKI) and its association 
with increased morbidity and mortality, therapeutic approaches for AKI are 
disappointing. This is largely attributed to poor understanding of the pathogenesis 
of AKI. Heparanase, an endoglycosidase that cleaves heparan sulfate, is involved in 
extracellular matrix turnover, inflammation, kidney dysfunction, diabetes, fibrosis, 
angiogenesis and cancer progression. The current study examined the involvement of 
heparanase in the pathogenesis of ischemic reperfusion (I/R) AKI in a mouse model 
and the protective effect of PG545, a potent heparanase inhibitor. I/R induced tubular 
damage and elevation in serum creatinine and blood urea nitrogen to a higher extent 
in heparanase over-expressing transgenic mice vs. wild type mice. Moreover, TGF-β, 
vimentin, fibronectin and α-smooth muscle actin, biomarkers of fibrosis, and TNFα, IL6 
and endothelin-1, biomarkers of inflammation, were upregulated in I/R induced AKI, 
primarily in heparanase transgenic mice, suggesting an adverse role of heparanase 
in the pathogenesis of AKI. Remarkably, pretreatment of mice with PG545 abolished 
kidney dysfunction and the up-regulation of heparanase, pro-inflammatory (i.e., IL-6) 
and pro-fibrotic (i.e., TGF-β) genes induced by I/R. The present study provides new 
insights into the involvement of heparanase in the pathogenesis of ischemic AKI. Our 
results demonstrate that heparanase plays a deleterious role in the development of 
renal injury and kidney dysfunction, attesting heparanase inhibition as a promising 
therapeutic approach for AKI.
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INTRODUCTION
Acute kidney injury (AKI) is a common clinical 
disorder affecting 2-7% of hospitalized patients and 
some 20-50% of critically ill subjects [1, 2]. Renal 
ischemia and hypoxia, toxic insult and sepsis are the 
leading causes of clinical AKI [1, 2]. Specifically, AKI 
is characterized by decreased oxygen delivery, depletion 
of cellular energy stores and accumulation of toxic 
metabolites. The cellular depletion of ATP, a hallmark 
of ischemic injury, leads to a series of morphological, 
biochemical and physiological derangements [2-4]. 
Reperfusion of ischemic tissue, although necessary for 
repair, has been shown to exacerbate AKI owing to the 
generation of reactive oxygen and nitrogen species [2-6]. 
Despite the advances in critical care medicine, AKI is still 
associated with high morbidity and mortality assumedly 
due to delayed detection of the disease and lack of 
effective treatment [7].
Several strategies were proposed to deal with 
AKI [2, 3, 8]. Among these are antioxidants including 
acetylcysteine, antioxidant enzyme mimetics, 
erythropoietin, peroxisome-proliferator-activated receptor 
agonists, inhibitors of poly(ADP-ribose) polymerase, 
carbon monoxide-releasing molecules and other measures 
to enhance hypoxia inducible factors, statins, and 
adenosine [2, 3, 6]. Unfortunately, the clinical efficacy 
of these therapeutic approaches is inconsistent and 
disappointing. Therefore, there is a great need to improve 
our understanding of the pathogenesis of AKI and design 
new strategies to prevent kidney damage during AKI. 
Heparan sulfate (HS) proteoglycans (HSPGs) 
are ubiquitous macromolecules associated with the cell 
surface and extracellular matrix (ECM) of a wide range 
of tissues including the kidney [9]. The HS chains bind 
to and assemble ECM proteins, thus playing important 
roles in ECM integrity, barrier function, and cell-ECM 
interactions [9]. HSPGs not only provide a storage depot 
for heparin binding molecules (i.e., growth factors, 
chemokines, enzymes) in the tissue microenvironment, 
but also regulate their accessibility, function and mode of 
action. It is therefore not surprising that a HS degrading 
enzyme, heparanase, is critically involved in pathological 
processes, including tumor growth, metastasis, 
angiogenesis, thrombosis, fibrosis, inflammation, 
autoimmunity and kidney dysfunction [10-18]. 
Emerging evidence suggests the involvement of 
heparanase in diabetic and nondiabetic proteinuric kidney 
diseases [19, 20]. For example, heparanase expression 
was shown to be upregulated in a number of animal 
models of renal diseases, including passive Heymann 
nephritis [21], puromycin aminonucleoside nephrosis 
(PAN) [22], adriamycin nephropathy (ADR-N) [23, 24], 
anti-glomerular basement membrane (GBM) nephritis 
[25], and diabetic nephropathy [26]; and in glomerular 
epithelial and endothelial cells cultured in ambient high 
glucose concentration [27]. As expected, heparanase 
upregulation was associated with reduced HS size in the 
GBM [20, 28]. Likewise, increased heparanase activity 
was detected in urine samples from diabetic patients with 
microalbuminuria [20, 27, 29-31], nondiabetic nephrotic 
syndrome, chronic kidney diseases (CKD) and kidney 
transplanted patients [29]. Notably, neutralization of 
heparanase activity, using either a sulfated oligosaccharide 
inhibitor (PI-88) or anti-heparanase antibodies, resulted in 
reduced proteinuria in ADR-N [32]. Similarly, Gil and 
colleagues [33] demonstrated that heparanase null mice 
fail to develop albuminuria and renal damage in response 
to streptozotocin-induced diabetes mellitus. Furthermore, 
a lower degree of albuminuria was detected in type 1 and 
type 2 diabetic mice treated with a heparanase inhibitor 
(SST0001 = Roneparstat) vs. mice treated with vehicle 
alone [33].
Although heparanase is recognized for its important 
role in diabetic nephropathy and other progressive CKD 
[34], its direct involvement and mode of action in the 
pathogenesis of AKI has not been studied thoroughly. 
We have previously reported that heparanase is involved 
in the onset and development of I/R-induced epithelial 
to mesenchymal transition (EMT) both in vitro and in 
vivo [35] and Lygizos et al [36] found that glomerular 
heparanase is activated during sepsis and contributes to 
septic AKI. Elucidation of the mechanism underlying 
the function of heparanase in AKI is critically important 
for the proper design of novel therapeutics approaches, 
including heparanase inhibitors such as PG545, 
Roneparstat and other compounds currently under 
intensive development and clinical testing [17, 37]. 
PG545, a synthetic fully sulfated HS mimetic with potent, 
long acting heparanase inhibiting capacity [38, 39], ended 
phase I clinical trial in cancer patients. The availability of 
PG545 and of heparanase over-expressing transgenic mice 
(Hpa-tg) [40] provides a most appropriate experimental 
platform to elucidate the involvement of heparanase in 
the pathogenesis of AKI. We report that PG545 abolished 
kidney dysfunction and the up-regulation of heparanase, 
pro-inflammatory (i.e., IL-6) and pro-fibrotic (i.e., TGF-β) 
mediators induced by I/R AKI. 
RESULTS
Acute ischemic injury up-regulates renal 
heparanase expression and enzymatic activity
Acute ischemic injury was induced by clamping 
both renal arteries for 30 minutes. As previously described 
[35], real-time PCR analyses (Figure 1A) confirmed an 
increment of heparanase expression in renal tissue of wt 
mice 48 h after ischemia and a more pronounced effect 
was noted in Hpa-tg mice at 72 h. Immunofluorescence 
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staining of renal tissue of wt animals confirmed that 
acute ischemic renal injury up-regulated heparanase in 
glomeruli, tubular cells and interstitial cells (Figure 1B). 
As demonstrated in Figure 1C, heparanase enzymatic 
activity was markedly enhanced following AKI in wt 
mice. Thus, when incubated with sulfate-labeled ECM, 
extracts from kidney of wt mice that were subjected to 
AKI released high amounts of HS degradation fragments 
(peak at fraction 23) as compared with sham control mice. 
As expected, kidney tissue from untreated Hpa-tg mice 
exhibited high basal heparanase activity (Figure 1D). 
These results are supported by qPCR analysis (Figure 1A) 
and immunostaining (Figure 1B) showing that heparanase 
expression and immunoreactivity were increased 
following AKI induction in both wt and Hpa-tg mice. 
Importantly, when wt and Hpa-tg mice were pretreated 
with PG545, heparanase gene expression (Figure 1A), 
immunoreactivity (Figure 1B) and enzymatic activity 
(Figure 1C, 1D) were profoundly suppressed, signifying 
the remarkable protective effect of PG545 against I/R. 
Heparanase induces acute ischemic injury
Histology
The structural changes in the kidney tissue of 
control and I/R wt and Hpa-tg mice were evaluated by 
PAS staining. We confirmed that at 48 h after I/R, wt mice 
Figure 1: Heparanase regulation by I/R kidney injury. A. Bar plot showing relative gene expression of HPSE evaluated by 
real-time PCR in renal tissue extract from wt and Hpa-tg mice untreated or pre-treated with PG545. Results were normalized to GAPDH 
expression. B. Representative immunofluorescence staining of heparanase in cortical renal tissues of wt and Hpa-tg mice 48 h after I/R 
kidney injury, with or without pre-treatment with PG545. Magnification 40X. Representative heparanase activity in the renal tissue of wt C. 
and Hpa-tg D. mice prior and post I/R in the presence or absence of PG545 pretreatment. I/R, ischemia/reperfusion.  *p < 0.05, **p < 0.01 
vs. corresponding sham; #p < 0.05, ##p < 0.01 vs. corresponding group w/o I/R ; $p < 0.05, $$p < 0.01 vs. corresponding wt; +p < 0.05, 
++p < 0.01 vs. untreated I/R corresponding group. 
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Figure 2: Ischemia/reperfusion (I/R) kidney injury in wt and Hpa-tg mice. I/R kidney injury was induced in wt and Hpa-tg 
mice by 30 minutes of clamping of both renal arteries. Mice were sacrificed after 48 hours. A. Representative images of PAS staining of 
paraffin-embedded cortex sections from various experimental groups. Magnification 40x. B. Electron microscopy micrographs of cortical 
renal tissue from wt and Hpa-tg mice that were subjected to 30 minutes of clamping of both renal arteries in the absence or presence of 
PG545 (0.4 mg/mouse, i.v). Note mitochondrial swelling and damage to mitochondrial cristae. Note normal ultrastructural appearance of 
mitochondria from mice treated with PG545. Magnification 12,000×.
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showed acute tubular necrosis which included tubular 
lysis, loss of brush border and sloughed debris in the 
tubular lumen spaces (Figure 2A). While in wt mice the 
damage was partially attenuated after 72 h, the injury in 
Hpa-tg mice was more profound and persistent also after 
72 h (not shown). In Hpa-tg mice there was a significant 
alteration in glomeruli and tubular structures. In particular, 
in Hpa-tg mice I/R produced a severe tubular damage 
with tubular dilatation, cell detachment from basement 
membrane, cast formation and loss of brush border (Figure 
2A). Notably, these effects were partially prevented in 
response to pretreatment with PG545. 
Ultrastructure alterations
Electron microscopy analyses of the renal tissue 
from the various experimental groups are presented in 
Figure 2B. As expected, induction of AKI resulted in 
remarkable mitochondrial alterations. Specifically, the 
mitochondria in the tubular cells of control wt and Hpa-
tg mice exhibited elongated cylindrical shape, whereas 
induction of AKI in both wt and Hpa-tg mice resulted 
in fragmented mitochondria and transformation from 
filamentous shape into short rods (Figure 2B). These 
deleterious alterations were more profound in Hpa-tg mice 
as was evident by spherical shape and matrix vacuoles 
(cristolysis). Pretreatment with PG545 of either wt or 
Hpa-tg mice partially restored the tubular mitochondrial 
morphological changes induced by AKI (Figure 2B) as 
was evident by nearly normal ultrastructural appearance 
of the mitochondrial cristae (Figure 2B).
Kidney function
Besides the histological changes, we further 
determined kidney function by measuring blood urea 
Figure 3: Biomarkers of kidney function in wt and Hpa-Tg mice after I/R. Effect of AKI on serum creatinine (SCr) A., B. and 
Blood urea nitrogen (BUN) C., D. 48 h A., C. and 72 h B., D. after I/R insult in wt and Hpa-tg mice. Note that AKI induced a more profound 
increase in both SCr and BUN in Hpa-tg mice as compared with wt mice. Additional two groups of wt and Hpa-tg mice were pretreated one 
day prior to AKI induction with PG545 (0.4 mg/mouse, ip) and sacrificed 48 h after renal injury A., C. *p < 0.05, **p < 0.01 vs. sham; #p 
< 0.01 vs. untreated mice; $ p < 0.05 vs. wt. 
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nitrogen (BUN) and serum creatinine (SCr) in the studied 
experimental groups (Figure 3). Induction of AKI in both 
wt and Hpa-tg mice was characterized by significant 
elevation of serum creatinine (SCr) (Figure 3A, 3B) and 
blood urea nitrogen (BUN) (Figure 3C, 3D), which was 
evident after 48 h and 72 h in both the wt and Hpa-tg mice 
(Figure 3), but was more prominent in the Hpa-tg mice 
after 72 h (Figure 3B, 3D). Pretreatment with PG545 
attenuated the elevation of SCr and BUN in the Hpa-tg 
mice (Figure 3A, 3C).
Heparanase inhibition attenuates epithelial 
mesenchymal transition
Gene expression analysis of total kidney lysates 
and immunofluorescence staining for α-SMA (Figure 4A, 
4B), vimentin (Figure 4C, 4D) and fibronectin (Figure 
4E, 4F) showed a slight or no up-regulation following 
acute ischemic renal insult in wt mice. In contrast, Hpa-tg 
mice displayed a significant and early activation of these 
parameters. Specifically, while in wt mice α-SMA (Figure 
4A) and vimentin (Figure 4C) expression in the kidney 
were slightly increased 48 h after acute renal ischemia and 
returned to basal levels after 72 h, Hpa-tg mice exhibited 
remarkable up regulation of SMA (Figure 4A), vimentin 
(Figure 4C) and FN (Figure 4E), both at 48 and 72 h. 
Similarly, we have previously reported the involvement 
of heparanase in epithelial mesenchymal transition, both 
in vitro and in vivo (35). Importantly, pretreatment with 
PG545 abolished the elevation in α-SMA, vimentin 
and fibronectin in the Hpa-tg mice (Figure 4A, 4C, 4E). 
Immunofluorescent staining confirmed the gene expression 
pattern on the protein level (Figure 4B, 4D, 4F), altogether 
emphasizing the involvement of heparanase in renal I/R 
and the associated epithelial mesenchymal transition.
Heparanase affects TGF-β, ET-1, IL6, TNFα and 
cathepsin L expression
In wt mice, 48 and 72 h after ischemia, TGF-β 
mRNA levels were similar to sham operated animals. 
In contrast, in Hpa-tg mice, acute I/R injury induced 
significant up-regulation of the TGF-β gene at both 48 h 
and 72 h (Figure 5A). A similar pattern of ET-1 (Figure 
5B) and IL6 (Figure 5C) upregulation was observed in 
Hpa-tg, but not wt mice that were subject to AKI, yet 
the upregulation of these genes was significant only at 
72 h. Induction of AKI in wt and Hpa-tg mice was also 
associated with enhanced expression of TNFα (Figure 
5D) and cathepsin L (Figure 5E), a key enzyme in the 
processing and activation of latent heparanase [41]. Again, 
the increased expression of these two genes was more 
profound in Hpa-tg mice. Remarkably, pretreatment with 
PG545 abolished the elevation in TGFβ, and to a lesser 
extent the upregulation of ET-1, IL-6, cathepsin L and 
TNFα. Altogether, it appears that biomarkers of fibrosis, 
EMT and inflammation were upregulated in I/R induced 
AKI, primarily in Hpa-tg mice, and this elevation was 
prevented to a large extent following pretreatment with 
PG545.
DISCUSSION
Despite the high prevalence of AKI and its 
association with an alarming increase in morbidity and 
mortality, the therapeutic approaches for AKI are still 
disappointing and rely mainly on supportive measures. 
This deficiency stems mainly from the poor understanding 
of the pathogenesis of AKI. The current research is 
therefore of special significance since it provides new 
insights into the mechanism underlying ischemic AKI, a 
major etiology of AKI. Specifically, we demonstrated that 
I/R of the kidney induced renal injury in both wt and Hpa-
tg mice as was evident by typical tubular damage including 
cell lysis, loss of brush border and sloughed debris in 
tubular lumen, which was more profound in Hpa-tg mice 
(Figure 2). The latter also displayed exaggerated elevation 
in SCr and BUN. Moreover, TGF-β, fibronectin, vimentin 
and α-smooth muscle actin, biomarkers of epithelial 
mesenchymal transition [35, 42], were upregulated in I/R 
induced AKI, especially in Hpa-tg mice, indicating an 
adverse role of heparanase in the pathogenesis AKI. This 
notion is further supported by the fact that pretreatment 
with PG545, a potent long acting inhibitor of heparanase 
[38], abolished the adverse renal changes induced by I/R 
and improved kidney function. Collectively, these findings 
clearly implicate heparanase in the pathophysiology of 
AKI, and suggest heparanase inhibitors as preventive/
therapeutic option for this common clinical setting. Given 
that transgenic mice may differ from their wt counterparts 
in various aspects, each experiment was performed with 
both wt and Hpa-tg mice, yielding the same results (i.e., 
upregulation of biomarkers of fibrosis, inflammation and 
EMT and down regulation/protection by the heparanase 
inhibitor PG545), albeit to a lower extent in wt mice. 
Overall it appears that the disease model is operating in 
wt mice in a manner similar to that seen in Hpa-tg mice. 
Despite the remarkable advances in nephrology, 
the pathophysiology of AKI remains largely obscured. 
Thus, research involving genetically modified animal 
models is a critical step in providing a new perspective 
into the pathophysiology of AKI. Indeed, the Hpa-tg 
mouse model [40] provides an appropriate experimental 
platform to elucidate the involvement of heparanase in 
the pathogenesis of AKI. Of note, Hpa-tg mice revealed 
increased levels of urinary creatinine at baseline, 
indicating a slight effect of heparanase on renal function 
even without induction of AKI (40), although this 
increase did not reach statistical significance as compared 
with wt mice (Figure 3). This result further supports 
the involvement of heparanase in kidney dysfunction, 
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Figure 4: Expression of epithelial mesenchymal transition (EMT) markers in wt vs. Hpa-tg mice after I/R kidney injury. 
Relative gene expression of A. α-SMA, C. VIM, and E. FN, were evaluated by real-time PCR in renal tissue extracts from wt and Hpa-tg 
mice that underwent I/R kidney injury with or without pre-treatment with PG545. Results were normalized to GAPDH expression. **p < 
0.001 vs. wt SHAM mice. I/R, ischemia/reperfusion. Representative immunofluorescence staining of α-SMA B., VIM D. and FN F. in renal 
tissue of wt and Hpa-tg mice that underwent 48 h of I/R kidney injury with or without pre-treatment with PG545. Magnification 40x. *p < 
0.05, **p < 0.01 vs. corresponding sham; #p < 0.05, ##p < 0.01 vs. corresponding group w/o I/R; $p < 0.05, $$p < 0.01 vs. corresponding 
wt; +p < 0.05, ++p < 0.01 vs. untreated I/R corresponding group. 
Oncotarget34198www.impactjournals.com/oncotarget
showing that the heparanase level in Hpa-tg mice is by 
itself not enough to induce acute damage, whereas its 
combination with I/R results in AKI to a higher extent 
in Hpa-tg than in wild type mice. Similar to other 
heparanase-inhibiting heparin-like compounds PG545 
displays some anti-coagulant properties, but this side 
effect was not detected in the AKI model nor in numerous 
tumor models in which mice are treated with PG545 for 
weeks [38]. Also, PG545 was found safe in phase I clinical 
trial in cancer patients [17, 37]. Our preliminary studies 
indicate that administration of PG545 post I/R failed to 
restore kidney damage and function. Yet, our pre-treatment 
approach maybe of clinical relevance in cases where AKI 
may occur (i.e., patients who undergo imaging involving 
i.v radiocontrast administration; patients undergoing major 
vascular surgery and cardiopulmonary bypass). So far 
there is no effective preventive treatment to minimize the 
incidence of AKI under these and other clinical settings, 
suggesting that PG545 may constitute a novel prophylactic 
therapeutic approach.
Unlike the Hpa-tg mice, results obtained with 
heparanase knockout mice [43] were not straightforward. 
AKI was induced by I/R also in the Hpa-KO mice, 
albeit to a lower extent than in wt and Hpa-tg mice, as 
revealed by the respective BUN and creatinine values. We 
have previously reported that the Hpa-KO mice reveal 
compensations for the lack of heparanase. These include 
up-regulation of matrix degrading enzymes and pro-
Figure 5: TGF-β, ET-1, IL6, TNFα and cathepsin L gene expression in wt vs. Hpa-tg mice after I/R kidney injury. Bar plots 
representing relative gene expression of TGF-β A., ET-1B., IL6 C., TNFα D. and Cathepsin L E., evaluated by real-time PCR in renal tissue 
extracts from wt and Hpa-tg mice that underwent I/R kidney injury with or without pre-treatment with PG545. Results were normalized to 
GAPDH expression. *p < 0.05, **p < 0.001 vs. wt sham; #p < 0.05, ##p < 0.01 vs. corresponding group w/o I/R ; $p < 0.05, $$p < 0.01 vs. 
corresponding wt; +p < 0.05, ++p < 0.01 vs. untreated I/R corresponding group. 
Oncotarget34199www.impactjournals.com/oncotarget
inflammatory mediators [43], resulting, paradoxically, in 
several phenotypes that closely resemble phenotypes seen 
in the Hpa-tg mice, making it difficult to interpretate data 
obtained with the Hpa-KO mice.
The availability of PG545 allows exploring 
potential therapeutic effects of heparanase inhibition in 
AKI. The latter is of special interest since in contrast to 
the well-established association between heparanase and 
glomerular diseases [20, 28], the role of heparanase in 
renal EMT associated with I/R injury has only recently 
been addressed [35]. Notably, a role for heparanase was 
identified in several proteinuric nephropathies [20, 23, 
28], mainly in the pathogenesis of diabetic nephropathy 
[26, 33] and in a model of septic AKI [36]. The latter 
is not surprising in light of the emerging data linking 
heparanase and inflammatory responses, suggesting a role 
of this enzyme in AKI. Indeed, Lygizos et al [36] found 
that glomerular heparanase is activated during sepsis and 
contributes to septic AKI. Specifically, the authors induced 
polymicrobial sepsis in mice using cecal ligation and 
puncture (CLP) in the presence or absence of competitive 
heparanase inhibitors (heparin or nonanticoagulant 
N-desulfated re-N-acetylated heparin). CLP-treated mice 
demonstrated early activation of glomerular heparanase 
with coincident loss of glomerular function, as indicated 
by an increase in blood urea nitrogen (BUN) and decrease 
in GFR. Administration of heparanase inhibitors two hours 
prior to CLP attenuated the deleterious consequences of 
sepsis, suggesting that glomerular heparanase is active 
during sepsis and contributes to septic renal dysfunction 
via uncharacterized mechanisms. In line with these 
findings, bilateral renal ischemia/reperfusion (I/R) in 
syndecan-1 deficient mice resulted in increased initial 
renal failure and tubular injury compared with wt mice 
[44]. In additional study, these authors have shown that 
within 24 h after renal I/R, HSPGs expressed at the ab-
luminal side of peri-tubular capillaries are induced to bind 
L-selectin and the monocyte chemoattractant protein-1, 
and that HSPGs facilitate monocyte extravasation [45]. 
A vicious circuit of heparanase-driven molecular events 
promoting chronic inflammation and renal injury has 
recently been described [11, 33]. This circuit is fueled 
by heterotypic interactions among glomerular, tubular, 
and immune cell compartments. It appears that latent 
heparanase, over-expressed by glomerular, epithelial 
and interstitial cells and post-translationally activated by 
cathepsin L, sustains continuous activation of kidney-
damaging macrophages via degradation of HS and release 
of chemokines anchored within the ECM network and 
cell surfaces [11]. Moreover, active heparanase governs 
macrophage activation via HS degradation fragments 
which activate TLR2 and TLR4 [46], leading to increased 
levels of TNF-α thereby creating inflammatory conditions 
fostering macrophage-mediated renal injury and up-
regulation of heparanase expression. This scenario is 
further supported by our findings. First, Hpa-tg mice 
were more susceptible to I/R-induced renal damage and 
kidney dysfunction as compared with their wt counterparts 
subjected to the same surgical maneuver. Second, using 
gene silencing approaches we further revealed an 
essential involvement of heparanase in the development 
of I/R-induced epithelial damage and suggested that its 
inhibition may signify a therapeutic approach to minimize/
prevent ischemic-induced renal fibrosis [35, 47]. Both, our 
previous in vitro studies applying cultured epithelial cells 
that were subjected to I/R [35, 47] and the current in vivo 
ischemic AKI model in wt and Hpa-tg mice exhibited 
upregulation of heparanase along over-expression of pro-
inflammatory and pro-fibrotic cytokines (i.e., TGF-β, IL-6, 
TNFα) as well as markers of EMT (i.e., VIM, FN, αSMA). 
Activated macrophages secrete TNFα and cathepsin L, 
which stimulate further production and activation of 
heparanase by these cells and by ischemia-induced renal 
injured cells. 
Upregulation of the TGF-β gene suggests that I/R 
triggers renal fibrogenesis, most likely through epithelial-
mesenchimal transition (EMT) of tubular cells [48]. 
Hparanase seems to play a major role in these processes 
as was evident by the exaggerated overexpression of 
TGF-β in Hpa-tg mice exposed to I/R. While the critical 
causal involvement of TGF-β in EMT and tissue fibrosis 
is well documented [42, 49], little is known about a 
crosstalk between heparanase and TGF-β [48]. Even more 
so, a crosstalk between heparanase and ET-1 [50, 51] in 
AKI has not been reported. Evidence for the combined 
involvement of heparanase, TGF-β and ET-1 in the 
fibrosis/inflammatory response to AKI is provided by 
showing that treatment with PG545 prior to I/R maintained 
a normal epithelial phenotype and abolished the EMT 
transcriptional program exemplified by a marked decrease 
in the levels of VIM, FN, α-SMA, IL-6, ET-1 and TGF-β. 
PG545, a potent heparin-like inhibitor of heparanase 
enzymatic activity, markedly decreases the ability of 
heparanase to release and potentiate the activity of ECM-
bound growth factors [37], further supporting PG545 as 
potential anti-fibrotic and kidney protective drug. Down-
regulation of heparanase expression in response to PG545 
was noted in 4T1 breast carcinoma model [52]. This 
effect was attributed in part to inhibition of growth factor-
stimulated ERK activation by PG545 and the resulting 
inhibitory effect on the transcription factor early growth 
response 1 (EGR1), known to induce heparanase gene 
expression [53]. Given the multi target genes regulated by 
EGR1 [54], the same mechanism may explain the effect 
of PG545 on the expression TGF-β, TNF-α, fibronectin 
and possibly other cytokines. Similarly, we have recently 
reported that heparanase activates Erk, p38 and JNK 
signaling, leading to increased c-Fos levels and induction 
of cytokine expression [55]. Suppression of this cascade 
by PG545 may affect the transcription of multiple genes 
including heparanase.
One of the studied parameters that might be 
of special relevance to kidney damage is ET-1, a 
vasoconstrictor released by endothelial cells [56]. ET-1 
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acts via two receptors subtypes ETA and ETB to modulate 
vasoconstriction, proliferation, inflammation, ECM 
production, and fibrosis in various target organs including 
the kidney [57, 58]. An evidence for the deleterious role of 
ET-1 in renal damage is derived from the nephroprotective 
effects of ET-1 antagonists in experimental and clinical 
models of AKI [59]. Previous studies have demonstrated 
a linkage between ET-1 and heparanase [60]. Such an 
association is essential for the development of DN, as was 
proven by the observation that heparanase-deficient mice 
were protected against diabetes-induced proteinuria and 
renal damage [33]. Addition of ET-1 increased heparanase 
mRNA expression and enzymatic activity in cultured 
podocytes [60]. Our results clearly show a positive 
correlation between renal heparanase and ET-1. Both were 
upregulated during AKI and inhibition of heparanase was 
associated with a decline in ET-1, suggesting a causal 
relationship between ET-1 and heparanase during ischemic 
AKI. 
In summary, our results indicate that heparanase is 
involved in the pathogenesis of ischemic AKI. Moreover, 
we demonstrated that pretreatment with a potent 
heparanase inhibitor (PG545) exerts nephroprotective 
effect against this clinical setting. Thus, our study 
provides a better perspective on the pathogenesis of AKI 
and the potential development of therapeutic/preventive 
interventions. 
MATERIALS AND METHODS
Animal model
Studies were conducted on wt (Balb/c) and 
corresponding heparanase-overexpressing (Hpa-tg) 
mice weighing 23-30 gr and maintained on standard rat 
chow and water ad libitum. Mice were crossed for over 
10 generations with Balb/c wt mice to produce pure 
genetic background. The Hpa-tg mice appeared normal 
and exhibited a normal life span and breeding behavior 
[40]. Western blot analysis revealed high expression of 
heparanase in the liver and kidney vs. low expression in 
the spleen of Hpa-tg vs. control mice [40, 61]. The study 
was performed according to the guidelines of the Animal 
Use and Care Committee, Technion (Haifa), and according 
to the Guide for the Care and Use of Laboratory Animals 
(NIH Publication no. 85-23, 1996) as approved by the 
local committee for supervision of animal experiments.
Induction of renal ischemia
Acute ischemia was induced in wt (Balb/c) and 
Hpa-tg mice as described by Mishra et al [62]. Wt and 
Hpa-tg mice were anesthetized with sodium pentobarbital 
(50 mg/kg, IP) and placed on a controlled heating table, 
keeping the body temperature at 37oC. Both right and 
left renal arteries were exposed and clamped for 30 min 
during which time the kidney was kept warm and moist. 
The clamp was then removed, the kidney was observed for 
the return of blood flow, and the abdominal wall incision 
was sutured. Mice were allowed to recover in a warmed 
cage for 48 and 72 h and blood samples were obtained 
at each time point for measurement of creatinine and 
urea. At these time points, kidney dysfunction and renal 
damage peak, especially 48 h post I/R [63]. Additional 
groups of wt and Hpa-tg mice were pretreated one day 
prior to AKI induction with PG545 (0.4 mg/mouse, ip). 
The kidneys were harvested and weighted. One half of the 
left kidney was snap frozen in liquid nitrogen and stored 
at −70°C until further molecular processing; the other half 
was fixed in formalin, paraffin-embedded, and sectioned 
(4 μm). Paraffin sections were stained with hematoxylin-
eosin and examined histologically. The right kidney was 
embedded in isopentane and frozen sections (4 μm) were 
obtained for immunohistochemistry [35]. Sham operated 
mice that underwent an identical procedure except renal 
artery clamping, served as controls. The number of mice 
per group (n) ranged from 6 to 12.
Quantitative real-time PCR
Total RNA was extracted with TRIzol (Sigma) 
and RNA (1 µg) was amplified using one step PCR 
amplification kit, according to the manufacturer’s 
(ABgene, Epsom, UK) instructions, essentially as 
described [55]. The moue primer sets used are listed in 
Table 1. 
Immunofluorescence
Sections (4 μm) were cut from paraffin embedded 
tissue and non-specific binding sites were saturated for 1 
h at 37°C with PBS, 5% BSA. Sections were incubated 
at 4°C overnight with primary antibodies diluted in PBS 
supplemented with 1% BSA. The primary antibodies used 
were directed against vimentin (Santa Cruz sc-7557), 
fibronectin (Santa Cruz sc-9068), α-SMA (Sigma A5228), 
or heparanase (Santa Cruz sc-25826). Primary antibodies 
were visualized with anti-mouse AlexaFluor-488, anti-
goat-FITC, anti-rabbit-Cy3, and anti-mouse-TR secondary 
antibodies. Cell nuclei were visualized by Hoechst 33258. 
Images were obtained by a confocal LeicaSP5 microscope 
[35].
Heparanase activity
Preparation of Na2
35SO4-labeled ECM-coated 35-
mm dishes and determination of heparanase activity were 
performed essentially as described [55, 64]. Briefly, freshly 
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collected renal tissues were homogenized and extracted 
in phosphate/citrate buffer (pH 5.2) by three cycles of 
freeze/thaw. Tissue lysates were incubated (overnight, 
37°C) with 35S-labeled ECM. The incubation medium 
(1 ml) containing sulfate-labeled degradation fragments 
was subjected to gel filtration on a Sepharose CL-6B 
column. Fractions (0.2 ml) were eluted with PBS and 
their radioactivity was counted in a β-scintillation counter. 
Degradation fragments of HS side chains produced by 
heparanase are eluted at 0.5 < Kav < 0.8 (fractions 12-29). 
Nearly intact HSPGs released from the ECM are eluted 
just after the Vo (Kav < 0.2, fractions 3-10) [59, 60]. These 
high molecular weight products are released by proteases 
that cleave the HSPG core protein.
Electron microscopy
Renal tissues from the various experimental groups 
were fixed in 3.5% glutaraldehyde and rinsed in 0.1 M 
sodium cacodylate buffer, pH 7.4. Tissue blocks (1 mm3) 
were post-fixed with 2% OsO4 in 0.2 M cacodylate buffer 
for 1 h, rinsed again in cacodylate buffer to remove excess 
osmium, immersed in saturated aqueous uranyl acetate, 
dehydrated in graded alcohol solutions, immersed in 
propylene oxide, and embedded in Epon 812. Ultrathin 
sections (80 nm) were mounted on 300-mesh, thin-
bar copper grid, counterstained with saturated uranyl 
acetate and lead citrate. Sections were examined with a 
transmission electron microscope (Jeol 1011 JEM) at 80 
KV.
Chemical analyses
Blood urea nitrogen and serum creatinine 
levels were determined using commercially available 
colorimetric kits (Cayman, Ann Arbor, MI; Bioassay 
Systems, Hayward, CA, respectively). 
Statistical analysis
Mean ± SEM of the real-time PCR data were 
calculated with Rest2009 software. Gene expression 
differences in mouse samples were analyzed by linear 
regression models with group (WT-sham, WT-I/R 48h, 
WT-I/R 72h, TG-sham, TG-I/R 48 h, TG-I/R 72 h) entered 
as a categorical variable. Bonferroni-corrected adjusted 
means and differences were computed using the WT-sham 
as the referent group. A Bonferroni-corrected p-value < 
0.05 was considered as statistically significant.
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Table 1: Primers sequence list
Gene Forward 5’-3’ Reverse 5’-3’
GAPDH GGCAAATTCAACGGCACAGT GTCTCGCTCCTGGAAGATGG
HPSE CAAGAACAGCACCTACTCAAG AGCAGTAGTCAAGGAGAAGC
α-SMA TGCTGGACTCTGGAGATGGT ACGAAGGAATAGCCACGCTC
VIM TCCAGAGAGAGGAAGCCGAA AAGGTCAAGACGTGCCAGAG
TGF-β GTGTGGAGCAACATGTGGAACTCTA CGCTGAATCGAAAGCCCTGTA
ET-1 TGCTGTTCGTGACTTTCC TGTTGACCCAGATGATGTC
 IL6 CTGCAAGAGACTTCCATCCAGTT GAAGTAGGGAAGGCCGTGG
TNFa CATCTTCTCAAAATTCGAGTGACAA TGGGAGTAGACAAGGTACAACCC
Cathepsin L GTGGACTGTTCTCACGCTCA ATCCACGAACCCTGTGTCA
Oncotarget34202www.impactjournals.com/oncotarget
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